TESARO, Inc. (NASDAQ:TSRO) – Equities researchers at Gabelli lifted their FY2017 earnings per share estimates for shares of TESARO in a research report issued on Wednesday. Gabelli analyst J. He now expects that the biopharmaceutical company will post earnings per share of ($8.05) for the year, up from their previous estimate of ($10.60). Gabelli also issued estimates for TESARO’s FY2018 earnings at ($5.10) EPS, FY2019 earnings at ($2.35) EPS, FY2020 earnings at $0.85 EPS and FY2021 earnings at $2.95 EPS.
TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business’s revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.72) EPS.
TRADEMARK VIOLATION NOTICE: “TESARO, Inc. Expected to Earn FY2017 Earnings of ($8.05) Per Share (TSRO)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/tesaro-inc-expected-to-earn-fy2017-earnings-of-8-05-per-share-tsro.html.
TSRO has been the subject of several other research reports. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Robert W. Baird reiterated a “hold” rating and issued a $120.00 target price on shares of TESARO in a research report on Friday. Wedbush reiterated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a research report on Monday, September 11th. ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Finally, Barclays PLC began coverage on TESARO in a research report on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 target price for the company. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $161.72.
TESARO (NASDAQ TSRO) opened at $91.09 on Friday. The company has a current ratio of 4.73, a quick ratio of 5.41 and a debt-to-equity ratio of 0.34. TESARO has a 12-month low of $89.00 and a 12-month high of $192.94.
In other TESARO news, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at approximately $1,171,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock worth $4,628,976 in the last ninety days. 40.50% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in TSRO. BlackRock Inc. raised its stake in shares of TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares in the last quarter. State Street Corp raised its stake in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after buying an additional 177,057 shares in the last quarter. BB Biotech AG raised its stake in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after buying an additional 53,408 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of TESARO in the 2nd quarter worth $100,301,000.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.